These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38319515)

  • 21. Preoperative CA19-9 levels and lymph node ratio are independent predictors of survival in patients with resected pancreatic ductal adenocarcinoma.
    Smith RA; Bosonnet L; Ghaneh P; Raraty M; Sutton R; Campbell F; Neoptolemos JP
    Dig Surg; 2008; 25(3):226-32. PubMed ID: 18577869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study.
    Miyata T; Hayashi H; Yamashita YI; Matsumura K; Nakao Y; Itoyama R; Yamao T; Tsukamoto M; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
    Ann Surg Oncol; 2021 Mar; 28(3):1572-1580. PubMed ID: 32804325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does Concurrent Cholestasis Alter the Prognostic Value of Preoperatively Elevated CA19-9 Serum Levels in Patients with Pancreatic Head Adenocarcinoma?
    Anger F; Lock JF; Klein I; Hartlapp I; Wiegering A; Germer CT; Kunzmann V; Löb S
    Ann Surg Oncol; 2022 Dec; 29(13):8523-8533. PubMed ID: 36094690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.
    Itoh S; Tsujita E; Fukuzawa K; Sugimachi K; Iguchi T; Ninomiya M; Maeda T; Kajiyama K; Adachi E; Uchiyama H; Utsunomiya T; Ikeda Y; Maekawa S; Toshima T; Harada N; Yoshizumi T; Mori M
    Pancreatology; 2021 Oct; 21(7):1356-1363. PubMed ID: 34426076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiotherapy.
    Suto H; Okano K; Oshima M; Ando Y; Matsukawa H; Takahashi S; Shibata T; Kamada H; Masaki T; Suzuki Y
    J Surg Oncol; 2022 Aug; 126(2):292-301. PubMed ID: 35289928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of metabolic adaptive capacity affects the prognosis among pancreatic ductal adenocarcinomas.
    Kanda T; Wakiya T; Ishido K; Kimura N; Fujita H; Yoshizawa T; Goto S; Tatara Y; Kijima H; Hakamada K
    J Gastroenterol; 2022 Oct; 57(10):798-811. PubMed ID: 35780404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
    Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
    Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer.
    Sakamoto T; Saito H; Amisaki M; Tokuyasu N; Honjo S; Fujiwara Y
    Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):278-284. PubMed ID: 30987900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of γ-glutamyltransferase-to-albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery.
    Li S; Xu H; Wu C; Wang W; Jin W; Gao H; Li H; Zhang S; Xu J; Zhang W; Xu S; Li T; Ni Q; Yu X; Liu L
    Cancer Med; 2019 Feb; 8(2):572-584. PubMed ID: 30632317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
    Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
    BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy.
    Ikenaga N; Nakata K; Hayashi M; Nakamura S; Abe T; Ideno N; Murakami M; Fujimori N; Fujita N; Isoda T; Baba S; Ishigami K; Oda Y; Nakamura M
    J Gastrointest Surg; 2023 Feb; 27(2):337-346. PubMed ID: 36652179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
    Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
    World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer.
    Tingle SJ; Severs GR; Goodfellow M; Moir JA; White SA
    J Surg Oncol; 2018 Sep; 118(4):680-686. PubMed ID: 30196571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
    Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
    Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a Biomarker-Based Scoring System Predicting Early Recurrence of Resectable Pancreatic Duct Adenocarcinoma.
    Ishido K; Kimura N; Wakiya T; Nagase H; Hara Y; Kanda T; Fujita H; Hakamada K
    Ann Surg Oncol; 2022 Feb; 29(2):1281-1293. PubMed ID: 34608555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
    Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
    Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative maximum standardized uptake value and carbohydrate antigen 19-9 were independent predictors of pathological stages and overall survival in Chinese patients with pancreatic duct adenocarcinoma.
    Gu X; Zhou R; Li C; Liu R; Zhao Z; Gao Y; Xu Y
    BMC Cancer; 2019 May; 19(1):456. PubMed ID: 31092213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma.
    Shimagaki T; Sugimachi K; Mano Y; Tomino T; Onishi E; Nakashima Y; Sugiyama M; Yamamoto M; Morita M; Shimokawa M; Yoshizumi T; Toh Y
    PLoS One; 2023; 18(7):e0288033. PubMed ID: 37450554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.